Online inquiry

IVTScrip™ mRNA-Anti-ANGPT2&VEGFA, RG-7221(Cap 0, Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ14292MR)

This product GTTS-WQ14292MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & Pseudo-UTP. It ecodes the monoclonal antibody that targets ANGPT2&VEGFA gene. The antibody can be applied in Solid tumors, Colorectal Cancer (CRC) Cancers (CRC) Cancer (CRC) research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_001118887.2; NM_001025366.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 285; 7422
UniProt ID O15123; P15692
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-ANGPT2&VEGFA, RG-7221(Cap 0, Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ14292MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ10694MR IVTScrip™ mRNA-Anti-ALB&IL17A, M-1095(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA M-1095
GTTS-WQ10510MR IVTScrip™ mRNA-Anti-APP, LY3002813(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA LY3002813
GTTS-WQ8983MR IVTScrip™ mRNA-Anti-IL22, ILV-094(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA ILV-094
GTTS-WQ7528MR IVTScrip™ mRNA-Anti-CLDN18, GC-182(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA GC-182
GTTS-WQ14793MR IVTScrip™ mRNA-Anti-CD40, SGN-40(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA SGN-40
GTTS-WQ8936MR IVTScrip™ mRNA-Anti-IL1B, IL-1 Trap(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA IL-1 Trap
GTTS-WQ4729MR IVTScrip™ mRNA-Anti-IL21, BOS161721(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA BOS161721
GTTS-WQ7214MR IVTScrip™ mRNA-Anti-CD19, FMC63 scFv-G4h-28-F9Z-TpERt CAR(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA FMC63 scFv-G4h-28-F9Z-TpERt CAR
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW